The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Factor VIII inhibitors in hemophilia A: rationale and latest evidence
Open accessAbstract
Factor VIII (FVIII) replacement therapy is the foundation of treatment in hemophilia A and is effective unless a patient develops an alloantibody (inhibitor) against exogenous FVIII. Inhibitor development is currently the most significant treatment complication seen in patients with hemophilia and is associated with considerable morbidity and a decreased quality of life. The development of an inhibitor is the result of a complex interaction between a patient’s immune system and genetic and environmental risk factors. The mainstay of treatment is the eradication of the inhibitor through immune tolerance. This review summarizes the current evidence regarding inhibitor risk factors, eradication, and hemostatic bypassing agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950
Lusher, J. M., Arkin, S., Abildgaard, C. F., & Schwartz, R. S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302183280701 · Cited by 476
Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom
Hay, C. R. M., Palmer, B., Chalmers, E., Liesner, R., Maclean, R., Rangarajan, S., Williams, M., Collins, P. W., & on behalf of United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) (2011) · Blood · doi:10.1182/blood-2010-09-308668 · Cited by 174
Cited by
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Oldenburg, J., Mahlangu, J. N., Kim, B., Schmitt, C., Callaghan, M. U., Young, G., Santagostino, E., Kruse-Jarres, R., Negrier, C., Kessler, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703068 · Cited by 1,121
Self-citationNext generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Chen, B.-M., Cheng, T.-L., & Roffler, S. R. (2021) · ACS Nano · doi:10.1021/acsnano.1c05922 · Cited by 563
The past and future of haemophilia: diagnosis, treatments, and its complications
Peyvandi, F., Garagiola, I., & Young, G. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01123-x · Cited by 505
Self-citationPipe, S. W., Shima, M., Lehle, M., Shapiro, A., Chebon, S., Fukutake, K., Key, N. S., Portron, A., Schmitt, C., Podolak-Dawidziak, M., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30054-7 · Cited by 391
Metadata
- Authors
- Witmer, C., & Young, G.
- Venue
- Therapeutic Advances in Hematology
- Publisher
- SAGE Publications
- Published
- 2012-10-30
- Volume
- 4
- Issue
- 1
- Pages
- 59-72
- ISSN
- 2040-6207 (ISSN-L)
- 2040-6215
- OpenAlex
- W2170563066
- Cited by
- 231
- References
- 3
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Factor VIII inhibitors in hemophilia A: rationale and latest evidence. https://app.cochat.ai/papers/10.1177/2040620712464509
- The paper
- Witmer, C., & Young, G. (2013). Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Therapeutic Advances in Hematology. https://doi.org/10.1177/2040620712464509
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.